AOD-9604

AOD-9604 was developed by Monash University and Metabolic Pharmaceuticals in Australia with the explicit goal of isolating the lipolytic (fat-burning) domain of human growth hormone. Full HGH has multiple effects including IGF-1 elevation, muscle growth, glucose elevation, and water retention — AOD-9604 was designed to retain only the fat metabolism effects while eliminating the others. The fragment (hGH 176–191) contains the region of the HGH molecule responsible for activating lipolysis in adipocytes — the release of stored fat for energy. By modifying the fragment with an additional tyrosine at the N-terminus, researchers created a stable, administrable form that interacts with fat cell receptors for lipolysis without binding the HGH receptor responsible for IGF-1 elevation and glucose effects. The compound achieved Australian TGA approval as a food additive (GRAS status) — a significant regulatory milestone that other research peptides cannot claim — though it failed to achieve FDA approval as an obesity drug when Phase 3 trials did not demonstrate sufficient superiority over placebo for the regulatory threshold.

Lipolysis stimulation without blood glucose effect is AOD-9604's defining and verified characteristic. Studies confirm it does not raise insulin levels, does not elevate blood glucose, and does not increase IGF-1 — the three HGH side effects most concerning for metabolic health and cancer risk. This safety profile makes it theoretically usable in diabetic or prediabetic individuals who could not tolerate full HGH. Fat loss in animal models has been impressive — obese rodents show significant body fat reduction with AOD-9604 treatment. Human results in clinical trials were more modest and context-dependent, with meaningful results in obese subjects that did not reach the threshold required for FDA obesity drug approval. Cartilage regeneration properties emerged from research beyond the original obesity indication. In vitro and animal studies suggest AOD-9604 promotes chondrocyte proliferation and cartilage matrix production, leading to investigation of its use in osteoarthritis. Some practitioners use it specifically for joint support rather than fat loss.

AOD-9604 has an excellent safety profile in both clinical trials and anecdotal use. Phase 2b trials in human subjects showed no significant adverse effects compared to placebo. GI discomfort has been reported with oral formulations, particularly at higher doses. Local injection site reactions are the most common finding with SubQ administration — mild redness or swelling that resolves within hours. The absence of IGF-1 elevation or glucose effects eliminates the primary safety concerns of HGH use, making AOD-9604 one of the lowest-risk research peptides from a systemic perspective.

Standard SubQ dose: 300–500 mcg/day, administered in the morning (fasted) for optimal fat mobilization activity. Oral dosing: Oral AOD-9604 is a theoretical convenience, but bioavailability from standard oral formulations is low. Some manufacturers offer specialized formulations (sublingual or enteric-coated) that may improve absorption. Doses for oral use are typically higher (1–2 mg/day) to compensate for reduced bioavailability. Timing: Fasted administration (morning, before food) is recommended to take advantage of the overnight fasting state for lipolysis and to avoid competition with insulin for receptor activity. Cycle length: AOD-9604 cycles are often run for 8–12 weeks, though the modest human efficacy means setting realistic expectations is important.

Australia: AOD-9604 received GRAS (Generally Recognized as Safe) status from the TGA as a food ingredient — a unique regulatory distinction. However, it does not have TGA approval as a therapeutic good. United States: Research chemical status. The FDA's Phase 3 failure means it is not on a regulatory approval pathway. Not a controlled substance. WADA: Not currently on the prohibited list. The absence of IGF-1 or HGH elevation means it does not trigger HGH-related doping tests.

AOD-9604 + Ipamorelin/CJC-1295: Adding AOD-9604's targeted fat lipolysis to a GH secretagogue stack provides fat loss specificity on top of the broader GH optimization benefits. This combination targets fat loss from multiple angles. AOD-9604 + BPC-157: For joint-focused applications, combining AOD-9604's cartilage repair properties with BPC-157's tendon and ligament healing creates a comprehensive connective tissue recovery protocol.

AOD-9604 — Common Questions